CCG | »çÈù&Æ¢·¹ÁöSahin&Tureci | |
Edit | 2020-12-21 ¿ÀÈÄ 8:22:07 | |
PIG | if you want | |
Home | https://bit.ly/3p8QQRM | |
SNS1 | https://bit.ly/3mBuuXv | |
SNS2 | https://bit.ly/38opCzW | |
SNS3 | https://on.ft.com/3h3PHZ3 | |
related | < HOME > < EDIT> | |
Rname | Tweet | |
»çÈù&Æ¢·¹Áö-Sahin&Tureci, Äڷγª¹é½Å, Germany | ||
¿ì±¸¸£ »çÈù Ugur Şahin [Ãâ»ý] 1965³â 9¿ù 29ÀÏ, ÅÍÅ° Iskenderun, Hatay, Turkey [Nationality] Turkish [Citizenship] Germany [Á÷¾÷] ±³¼ö, ¹ÙÀÌ¿À¿£Å×Å© CEO ¿ÜÁñ·½ Æ¢·¹Áö Özlem Türeci [Ãâ»ý] 1967³â, µ¶ÀÏ Lastrup, Lower Saxony, Germany [Á÷¾÷] °úÇÐÀÚ, ¹ÙÀÌ¿À¿£Å×Å©ÀÇ ÃÖ°íÀÇ·áÃ¥ÀÓÀÚ(CMO) ¹Ì±¹ Á¦¾àȸ»ç ÈÀÌÀÚ¿Í ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) ¹é½ÅÀ» ÇÔ²² °³¹ß, ¼¼°èÀû À̸ñÀ» ²ö µ¶ÀÏ ¹ÙÀÌ¿À¿£Å×Å©´Â ÅÍÅ° À̹ÎÀÚ 2¼¼ Ãâ½ÅÀÇ µ¶ÀÏÀÎ ºÎºÎ°¡ ¼¼¿ü´Ù°í ¿µ±¹ ÀÏ°£ °¡µð¾ðÀÌ 2020³â 11¿ù 9ÀÏ º¸µµÇß´Ù. º¸µµ¿¡ µû¸£¸é ¹ÙÀÌ¿À¿£Å×Å©´Â 2008³â ¿ì±¸¸£ »çÈù(55)°ú ¿ÜÁñ·½ Æ¢·¹Áö(53) ºÎºÎ°¡ °øµ¿ â¾÷Çß´Ù. ÀÌµé ºÎºÎ ¸ðµÎ 1960³â´ë µ¶ÀÏ¿¡¼ ÀÏÇÏ·Á°í ÅÍÅ°¿¡¼ °Ç³Ê¿Â ÀÌÁÖ ³ëµ¿ÀÚ °¡Á¤¿¡¼ ž µ¶ÀÏ¿¡¼ ÀÚ¶ó³ ÀüÇüÀûÀÎ À̹Π2¼¼ 'Èë¼öÀú' Ãâ½ÅÀÌ´Ù. »çÈùÀº ÅÍÅ°¿¡¼ ž 4»ì ¶§ µ¶ÀÏ·Î ÀÌÁÖÇß°í Æ¢·¹Áö´Â µ¶ÀÏ¿¡¼ ž´Ù. µ¶ÀÏ º£¸¦¸° Áö¿ªÁö Ÿ°Ô½º½´ÇÇ°ÖÀº "ÀÌµé ºÎºÎÀÇ ¼º°øÀº û°ú¹° °¡°Ô¿¡¼ ÀÏÇÏ´Â ÀúÇз °èÃþ Á¤µµ·Î ¼ö½Ê ³â°£ ¿©°ÜÁ³´ø ÅÍÅ° À̹ÎÀÚÀÇ Äè°Å´Ù"¶ó°í Æò°¡Çß´Ù. ÀǴ븦 Á¹¾÷ÇÑ µÚ ¿¬±¸¿øÀ¸·Î ÀÏÇÏ´ø À̵éÀº 2002³â µ¶ÀÏÀÇ ÇÑ ´ëÇп¡¼ ¸¸³ª °áÈ¥Çß´Ù°í ÇÑ´Ù. °áÈ¥½Äµµ ½ÇÇè½Ç¿¡¼ ½ÇÇ躹À» ÀÔ°í ¿Ã·È°í, °áÈ¥½Ä ´çÀÏ °üû¿¡ È¥ÀÎ ½Å°í¸¦ ÇÑ µÚ ´Ù½Ã ¿¬±¸½Ç·Î µ¹¾Æ¿ÔÀ» Á¤µµ·Î µÎ »ç¶÷ ¸ðµÎ ¿¬±¸¿¡¸¸ ¸ôµÎÇß´Ù. ¹ÙÀÌ¿À¿£Å×Å©´Â ¹ÙÀÌ·¯½º ¹é½ÅÀÌ ¾Æ´Ï¶ó Ç×¾Ï ¸é¿ªÄ¡·á¹ý °³¹ßÀÌ ÁÖ·Â ºÐ¾ßÀΠȸ»çÁö¸¸ ¿ÃÇØ ÃÊ Äڷγª19°¡ Áß±¹¿¡¼ ¹ßº´ÇÏÀÚ '±¤¼Ó'À̶ó´Â À̸§ÀÇ °³¹ßÆÀÀ» 500¸í ±Ô¸ð·Î ±¸¼ºÇÏ°í À绡¸® ¹é½Å °³¹ßÀ» ½ÃÀÛÇß´Ù. ÀÌ È¸»çÀÇ ÃÖ°í°æ¿µÀÚ(CEO)ÀÎ ³²Æí »çÈùÀº µ¶ÀÏ ÀâÁö¿Í ÀÎÅͺ信¼ "¿ÃÇØ 1¿ù Äڷγª19¿¡ °üÇÑ ±â»ç¸¦ ÀоúÀ» ¶§ ¾Æ³»¿¡°Ô '4¿ùÀÌ¸é µ¶Àϵµ Çб³ ¹®À» ´ÝÀ» °Å¾ß'¶ó°í Çß´Ù"¶ó°í ¸»Çß´Ù. ½ÇÁ¦·Î µ¶ÀÏÀº 3¿ù ÈÞ±³·ÉÀ» ³»·È´Âµ¥ ¹ÙÀÌ¿À¿£Å×Å©´Â ÀÌ¹Ì 20°¡ÁöÀÇ ¹é½Å Èĺ¸ ¹°ÁúÀ» °³¹ßÇØ ³½ ¶§¿´´Ù. ºô °ÔÀÌÃ÷ ¸¶ÀÌÅ©·Î¼ÒÇÁÆ® â¾÷ÀÚ°¡ 5õ500¸¸ ´Þ·¯(¾à 616¾ï¿ø)¸¦ ÅõÀÚÇϱ⵵ ÇÑ ¹ÙÀÌ¿À¿£Å×Å©´Â ¹é½Å °³¹ß ¼Ò½Ä¿¡ 9ÀÏ ÁÖ°¡°¡ 23.4% ±ÞµîÇØ ½Ã°¡ÃѾ×ÀÌ 219¾ï ´Þ·¯(¾à 25Á¶¿ø)°¡ µÆ´Ù. ¿µ±¹ µ¥Àϸ®¸ÞÀÏÀº ÀÌµé ºÎºÎ°¡ ¾ï¸¸ÀåÀÚ°¡ µÉ °¡´É¼ºÀÌ Å©Áö¸¸ ¿©ÀüÈ÷ ÀÚÀü°Å¸¦ Ÿ°í ÃâÅð±ÙÇÏ¸é¼ °Ë¼ÒÇÑ Åµµ·Î º¯ÇÔ¾øÀÌ ¿¬±¸¿¡ Àü³äÇÏ°í ÀÖ´Ù°í ÀüÇß´Ù. (from yna.co.kr) ------------------------------- ÈÀÌÀÚ¿Í °øµ¿À¸·Î ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) ¹é½ÅÀ» °³¹ßÇÑ µ¶ÀÏ ¹ÙÀÌ¿À¿£Å×Å© â¾÷ÁÖÀÌÀÚ ÃÖ°í°æ¿µÀÚ(CEO)ÀÎ ¿ì±¸¸£ »çÈù(55)ÀÌ ¼¼°è 500´ë ºÎÀÚÀÇ ¹Ý¿¿¡ ¿Ã¶ú´Ù°í ºí·ë¹ö±×Åë½ÅÀÌ 4ÀÏ(ÇöÁö½Ã°£) º¸µµÇß´Ù. ¹é½Å °³¹ß·Î ȸ»ç ÁÖ°¡°¡ ±ÞµîÇÑ ´öÀÌ´Ù. º¸µµ¿¡ µû¸£¸é »çÈù CEOÀÇ ¼ø ÀÚ»êÀº 51¾ï ´Þ·¯(¾à 5Á¶ 5590¾ï¿ø)·Î 'ºí·ë¹ö±× ¾ï¸¸ÀåÀÚ Áö¼ö'»ó ¼¼°è 493¹ø° ºÎÀÚ°¡ µÆ´Ù. »çÈùÀº ¹ÙÀÌ¿À¿£Å×Å© ÁÖ½ÄÀ» 18% º¸À¯Çߴµ¥, ¿ÃÇØ µé¾î ÁÖ°¡°¡ 250% ÀÌ»ó ±ÞµîÇß´Ù. ƯÈ÷ ¿µ±¹ÀÌ ÈÀÌÀÚ ¹é½ÅÀ» ½ÂÀÎÇÏ°Ú´Ù´Â °èȹÀ» ¹àÈù ÀÌÈÄ¿¡¸¸ 10% ÀÌ»ó ¿Ã¶ú´Ù. ´Ü 10°³¿ù ¸¸¿¡ Äڷγª19 ¹é½ÅÀ» °³¹ßÇÑ »çÈùÀº ¡®Èë¼öÀú ½ÅÈ¡¯·Î ºÒ¸°´Ù. ÅÍÅ° ³ëµ¿ÀÚ Ãâ½ÅÀÇ ºÎ¸ð¸¦ µÐ À̹Π2¼¼´Ù. 2008³â ¹ÙÀÌ¿À¿£Å×Å©¸¦ ÇÔ²² ¼³¸³ÇÑ ºÎÀÎ ¿ÜÁñ·½ Æ¢·¹Áö(53)µµ ¿ª½Ã ÅÍÅ°°è À̹Π°¡Á¤ Ãâ½ÅÀÌ´Ù. [from Áß¾ÓÀϺ¸] ------------------------------------ FT ¼±Á¤ ¿ÃÇØÀÇ Àι°Àº ¹ÙÀÌ¿À¿£Å×Å© CEO ºÎºÎ "¾Æ¹« Àϵµ ÇÏÁö ¾ÊÀ¸¸é ÁÁÀº ÀÏÀº ÀϾÁö ¾Ê´Â´Ù"-¼ö»ó ¼Ò°¨ ¿µ±¹ ÆÄÀ̳½¼ÈŸÀÓ½º(FT)ÀÇ ¿ÃÇØÀÇ Àι°¿¡ Äڷγª19 ¹é½ÅÀ» ´Ü 10°³¿ù ¸¸¿¡ °³¹ßÇÑ ¿ì±¸¸£ »çÈù ¹ÙÀÌ¿À¿£Å×Å© â¾÷ÀÚ °â ÃÖ°í°æ¿µÀÚ(CEO)¿Í ºÎÀÎ ¿ÍÁñ·½ Æ¢·¹Áö ¹Ú»ç°¡ »ÌÇû´Ù. FT´Â 2020³â 12¿ù 15ÀÏ "¹Ì±¹ Á¦¾à»ç ÈÀÌÀÚ¿Í Äڷγª19 ¹é½ÅÀ» °øµ¿ °³¹ßÇÑ »çÈù CEO¡¤ ¿ÜÁñ·½ Æ¢·¹Áö ºÎºÎ¸¦ 'FT ¿ÃÇØÀÇ Àι°(FT People of the Year)'·Î ¼±Á¤Çß´Ù"°í º¸µµÇß´Ù. FT´Â "»çÈù°ú Æ¢·¹Áö ºÎºÎ´Â Äڷγª19 º´¿ø±ÕÀÇ À¯ÀüÀÚ ¹è¿ÀÌ ¹àÇôÁø Áö 1³âµµ ä ¾È µÅ ¾ÈÀüÇÏ°í È¿°úÀûÀÎ ¹é½ÅÀ» °³¹ßÇß´Ù"¸ç "¿ì¸® ½Ã´ëÀÇ °¡Àå À§´ëÇÑ ÀÇÇÐÀû ¹ß°ß"À̶ó°í Æò°¡Çß´Ù. ¿µ±¹ À̽ºÆ® ¾Þ±Û¸®¾Æ´ëÇÐÀÇ Æú ÇåÅÍ ±³¼ö´Â "Äڷγª19 ¹é½ÅÀº ¿¡µå¿öµå Á¦³ÊÀÇ 1786³â ¼öµÎ ¹é½Å ÀÌÈÄ °¡Àå »¡¸® °³¹ßµÆ´Ù"¸ç "ÀÌÀü ±â·ÏÀº 4³â ¸¸¿¡ °³¹ßµÈ º¼°Å¸® ¹é½ÅÀ̾ú´Ù"¶ó°í ¼³¸íÇß´Ù. ÅÍÅ° À̹ÎÀÚ °¡Á¤ Ãâ½ÅÀÎ »çÈù ºÎºÎ´Â ¾Ï Ä¡·á ¿¬±¸¿¡ 30³â ÀÌ»ó Àü³äÇØ¿À´Ù Äڷγª19 °ü·Ã ³í¹®À» ÀÐ°í ¹é½Å °³¹ß¿¡ ¶Ù¾îµé¾ú´Ù. À̵éÀº ±âÁ¸¿¡ ½×¾Æ¿Â mRNA ¿¬±¸ ¼º°ú¸¦ ¹é½Å¿¡ Á¢¸ñÇØ ºü¸£°Ô ¹é½Å °³¹ßÇß°í, 2020³â 12¿ù ¿µ±¹(2ÀÏ)°ú ¹Ì±¹ ±ÔÁ¦´ç±¹(11ÀÏ)ÀÇ ½ÂÀÎÀ» ¹Þ¾Ò´Ù. FT´Â Äڷγª19 ¹é½Å °³¹ß ¼±µÎÁÖÀÚÀÎ ¹Ì±¹ ¸ð´õ³ª¿Í ¿µ±¹ ¾Æ½ºÆ®¶óÁ¦³×Ä«, Áß±¹°ú ·¯½Ã¾Æ ¿¬±¸ÁøµéÀ» Á¦Ä¡°í »çÈù CEO°¡ ¼±Á¤µÈ µ¥ ´ëÇØ "¼¼°è¿¡¼ °¡Àå ½Å·ÚÇÒ ¼ö ÀÖ´Â ±ÔÁ¦±â°ü µÎ °÷À¸·ÎºÎÅÍ ½ÂÀÎÀ» ¹ÞÀº ÃÖÃÊÀÇ ¹é½Å °³¹ßÀÚ"¶ó°í ÀÌÀ¯¸¦ ¼³¸íÇß´Ù. FT¿¡ µû¸£¸é »çÈù CEO´Â Äڷγª19ÀÇ À̸§µµ ºÙ±â ÀüÀÎ 2020³â 1¿ù ¾Æ³» Æ¢·¹Áö ¹Ú»ç¿Í ÇÔ²² Áß±¹ Èĺ£À̼ºÀ» °Å¸ÇÑ Á¤Ã¼ºÒ¸íÀÇ È£Èí±â Áúȯ¿¡ ´ëÇÑ ³í¹®À» ±¹Á¦ÇмúÁö '·£½Ë'(Lancet)¿¡ ¹ßÇ¥Çß´Ù. °¨¿°·üÀÌ ³î¶ó¿î ¼öÁØÀÌ¶ó ¿¹»óº¸´Ù ÈξÀ ºü¸¥ ¼Óµµ·Î È®»êÇÒ ¼ö ÀÖ´Ù´Â ³»¿ëÀ̾ú´Ù. ÀÌÈÄ »çÈù CEO´Â ¼¼°èº¸°Ç±â±¸(WHO)°¡ ¼¼°èÀû ´ëÀ¯ÇàÀ» ¼±¾ð(3¿ù11ÀÏ)Çϱ⠵Π´Þ ÀüºÎÅÍ ¹é½Å °³¹ßÀ» Á¦¾ÈÇß°í, °ð¹Ù·Î °³¹ß¿¡ Âø¼öÇß´Ù. ±×¸®°í ºÒ°ú 3°³¿ù ¸¸¿¡ ¿ø¼þÀÌ¿Í Á㸦 ´ë»óÀ¸·Î ÇÑ ½ÃÇè¿¡¼ ¼º°øÀûÀÎ °á°ú¸¦ ¾ò¾ú´Ù. »çÈù CEO ºÎºÎ´Â ¼¼°è ÁÖ¿ä ¾ð·ÐµéÀÌ "À̹Π¼º°ø »ç·Ê'·Î ±×¸®´Â µ¥ ´ëÇØ ÀڽŵéÀÇ ¹è°æº¸´Ù °úÇп¡ ÃÊÁ¡À» ¸ÂÃç´Þ¶ó°í ´çºÎÇß´Ù. µÎ ºÎºÎ´Â ³¡À¸·Î »çȸ¿¡ ÀüÇÏ°í ½ÍÀº ¸»ÀÌ ÀֳĴ FTÀÇ ¿äû¿¡ "¾Æ¹« Àϵµ ÇÏÁö ¾ÊÀ¸¸é ÁÁÀº ÀÏÀº ÀϾÁö ¾Ê´Â´Ù"¶ó´Â µ¶ÀÏ ¾î¸°ÀÌÃ¥ ÀÛ°¡ ¿¡¸®È÷ ij½ºÆ®³Ê Ã¥ ¼Ó ±¸ÀýÀ» ¾ð±ÞÇÏ´Â °ÍÀ¸·Î ´ë½ÅÇß´Ù. ÀÌ ¹®ÀåÀº »çÈù CEO ¸ð±³ÀÎ Äþ¸¥´ëÀÇ ±³ÈÆÀ̱⵵ ÇÏ´Ù. (from news1.kr 2020³â 12¿ù 16ÀÏ) ------------------------------------ Ugur Şahin [Born] September 29, 1965 Iskenderun, Hatay, Turkey [Nationality] Turkish [Citizenship] Germany [Alma mater] University of Cologne Saarland University [Occupation] Professor of Oncology Chief Executive Officer Company Founder [Employer] University of Cologne Saarland University University Hospital Zurich University Medical Center Mainz BioNTech [Organization] German Society of Immunology American Association for Cancer Research American Society of Clinical Oncology [Known for] BioNTech BNT162b2 vaccine [Net worth] around $5.2 billion USD (2020.12) Ugur Şahin (born September 29, 1965) is a German physician, oncologist and entrepreneur of Turkish origin. His main fields of research are cancer research and immunology. He has been Professor of Experimental Oncology at the III Medical Clinic of the University of Mainz since 2006, and chairman of the board and CEO of BioNTech SE since 2008, a company that he co-founded with his wife, Özlem Türeci. Şahin is considered one of the leading COVID-19 vaccine developers. He and his spouse are among the hundred wealthiest people in Germany. As of 2020, Forbes estimated his net worth at $5.2 billion USD. [Career] Şahin worked as a physician for internal medicine and hematology/oncology from 1991 to 2000 at the University Hospital of Cologne [de] and then at the Saarland University Hospital in Homburg. He habilitated in 1999 in the field of molecular medicine and immunology. After working at the Institute for Experimental Immunology of the University Hospital Zurich in 2000, he moved to the University Medical Center Mainz. There, he has been working in various leading positions in cancer research and immunology since 2001 and has been a professor for experimental oncology at the III. medical clinic since 2006. Şahin works on identifying and characterizing new target molecules (antigens) for the immunotherapy of cancer tumors, e.g. breast cancer, prostate cancer, lung cancer, and other dangerous cancers. The aim is to develop a cancer vaccine based on ribonucleic acid (RNA), a messenger substance with genetic information that triggers a corresponding reaction of the immune system, leading to the inhibition and regression of tumors. These RNA vaccines do not cause a permanent genetic change in the genetic material of the cells. However, they are, in simple terms, dissolved again after "single-use" to form a protein. One problem is to develop a genetic engineering process so that these vaccines trigger a direct and targeted response from the immune system after injection. In developing such optimized RNA chains, Uğur Şahin and its research team have achieved remarkable success in recent years. Şahin sees himself as an immune engineer who tries to use the body's antiviral mechanisms to treat, for example, cancer when the immune system is otherwise unable to fight it. He sees his vision in guiding the immune system to "protect us from or alleviate certain diseases. ------------------------ Özlem Türeci [Born] 1967 Lastrup, Lower Saxony, Germany [Citizenship]German [Alma mater] Saarland University [Occupation] Chief Medical Officer University lecturer Scientist [Employer] University of Mainz BioNTech [Known for] BioNTech BNT162b2 vaccine [Office] CMO BioNTech SE [Spouse(s)] Uğur Şahin Özlem Türeci (born 1967) is a German physician, mmunologist and businessperson. She is co-founder and chief medical officer of BioNTech. Türeci and her team developed a vaccine against SARS-CoV-2. [Career] Türeci is co-founder and chief medical officer of BioNTech, president of the Mainz, Germany-based non-profit Association for Cancer Immunotherapy (CIMT), co-initiator and chair of the Rhine-Main region-based non-profit Cluster for Individualized Immune Intervention (Ci3), and lecturer at the University of Mainz. She is a pioneer in cancer immunotherapy. In 2001, Türeci co-founded Ganymed Pharmaceuticals as its chief scientific officer, going on to become its chief executive officer in 2008. Ganymed is now a subsidiary of Astellas Pharma, having been acquired in 2016 for ¢æ1.3 billion in Germany's then largest biotech deal to date. During the 2020 COVID-19 pandemic, Türeci shifted her research focus to developing a vaccine against SARS-CoV-2, the virus responsible for COVID-19, in partnership with Pfizer. On 11 November 2020, Pfizer reported that the vaccine developed by Türeci and her team was more than 90 percent effective in providing immunity to the virus. [BioNTech is now worth $25.8 billion (21.8 billion euros), more than Germany's largest lender Deutsche Bank.] ----------------------------------- FT People of the Year: BioNTech¡¯s Ugur Sahin and Ozlem Tureci By developing a Covid vaccine in less than a year, the couple achieved a remarkable scientific and business success [by Joe Miller in Frankfurt and Clive Cookson in London DECEMBER 16 2020] In the 11 months since they devoted themselves to stemming the deadliest pandemic in over a century, Ozlem Tureci and Ugur Sahin's precious few private moments have been spent exercising along deserted suburban streets near their home in the German city of Mainz, listening to ¡®80s pop playlists. Deluged by paperwork from regulators around the world last week, the co-founders of BioNTech missed the TV footage of 90-year-old Margaret Keenan rolling up her sleeve at a hospital in Coventry in the UK to become the first patient injected with their approved Covid-19 vaccine — the news trickling in via messages from friends and colleagues. The symbolism of those images, however, was unmistakable: it effectively kickstarted humanity's fightback against a disease which has claimed more than 1.6m lives. ¡°We were nervous,¡± admits Dr Sahin, whose quiet confidence has seemed shatterproof over the past year. Despite having seen their jab administered to more than 22,000 people in clinical studies across six countries, he says "t is different when people are vaccinated for the first time outside a trial, in the real world setting". (from naver.com wikipedia.org µî) BioNTech, Best, influence(+) ~ (PIG: time-variant) Positive Influence GRADE (PIG): B+
|